Clinical Report: Navigating Office Dynamics in the Management of Geographic Atrophy
Overview
This report discusses the evolution of geographic atrophy (GA) management, emphasizing early diagnosis and the use of advanced imaging techniques. The introduction of FDA-approved therapies has transformed treatment options, allowing for proactive patient care and improved outcomes.
Background
Geographic atrophy (GA) is a severe form of dry age-related macular degeneration (AMD) that leads to significant vision loss. Historically, patients were often referred too late for effective intervention, limiting treatment options. Recent advancements in imaging and the approval of new therapies have shifted the focus towards early detection and proactive management, which is crucial for preserving vision.
Data Highlights
No numerical data provided in the article.
Key Findings
- Early intervention in GA management is essential for slowing disease progression.
- Advanced imaging modalities, such as fundus autofluorescence and optical coherence tomography, are critical for monitoring GA.
- Two FDA-approved therapies for GA, pegcetacoplan and avacincaptad pegol, have been introduced in 2023.
- Safety considerations, including risks of retinal vasculitis and inflammation, are vital in treatment planning.
- Patient communication regarding treatment expectations is crucial, as current therapies do not reverse GA but slow its progression.
Clinical Implications
Clinicians should prioritize early diagnosis and utilize advanced imaging techniques to monitor GA progression. Clear communication with patients about treatment goals and risks is essential to ensure informed decision-making and enhance patient engagement in their care.
Conclusion
The management of geographic atrophy has evolved towards a more proactive and patient-centered approach, significantly improving patient outcomes and engagement. Continued emphasis on early detection and effective communication will be key in navigating the complexities of GA treatment.
References
- Mona Camacci, MD, MS, Retina Consultants of South Carolina, 2025 -- Navigating Office Dynamics in the Management of Geographic Atrophy
- Optometric Management, 2025 -- Talking to Patients About Geographic Atrophy
- Optometric Management, 2025 -- Identifying Geographic Atrophy Biomarkers
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University, 2025
- Optometric Management — The Critical Role of Co-Management
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- SYFOVRE- pegcetacoplan injection, solution
- HIGHLIGHTS OF PRESCRIBING INFORMATION
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.